Cheng Andrew 4

What Happened

• Andrew Cheng, a director of Vera Therapeutics, received a grant/award of 17,084 shares classified as a derivative on 2026-05-21. The filing reports $0.00 per share (no cash paid at grant) and a reported aggregate value of $0. This is an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26 (5 days after the transaction; outside the typical 2-business-day Form 4 window).
• Reported price: $0.00 per share; aggregate reported value: $0.
• Shares owned after transaction: not disclosed in the filing.
• Footnote (vesting): The shares vest in full on the earlier of the first anniversary of the grant date or the Company’s 2027 annual meeting, subject to Cheng’s continuous service. The shares also vest in full upon a change in control, subject to continuous service.
• Transaction type: Derivative award (grant) — code A.

Context

• This award is a conditional grant, not an immediate cash transaction. Because vesting is contingent on continued service (or a change in control), the recipient does not necessarily have immediate unrestricted stock to sell.
• Awards and grants are common for directors and executives as compensation; they are different from open-market purchases (which can signal bullishness) or sales (which may signal liquidity needs).